Successful late-stage trial results for once-a-day eye drug announced

The AP (8/27) reports that on Aug. 27, ISTA Pharmaceuticals, Inc. announced “successful late-stage clinical trial results for Xibrom QD [bromfenac ophthalmic], a new once-per-day eye drug.” According to the company, “Xibrom QD eye drops were significantly better than a placebo at eliminating eye inflammation 15 days after cataract surgery” in “299 patients who had cataract surgery on one eye.” In addition, the medication “achieved a secondary goal of eliminating eye pain one day after surgery.” The AP notes that “the drug is a once-per-day version of Xibrom [bromfenac ophthalmic], a drug that is already on the market, but is intended to be used twice a day.” ISTA now “expects to file for Food and Drug Administration approval of Xibrom QD by the end of the year


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: